Pioneering biomarker technologies for Cancer therapies

Our biomarkers are used to identify the right patient, the right drug and the right dose.

Biomarker tests


magnifying

Using our biomarker tests provides more effective treatment for patients and economic savings for the healthcare system. Our colorectal cancer tests are validated using thousands of patient samples and are set to transform the current treatment pathway.

Biomarker platforms


testtubes

Our companion diagnostic biomarker platforms are used to discover biomarkers which improve both the benefit and risk profiles of pipeline drugs.

CancerNav®

A functional genome-wide screen to discover companion diagnostic biomarkers that predict efficacy.

ToxNavTM

A genome-wide screen using the principles of toxgnostics to discover biomarkers that predict drug specific side-effects.

We are looking to partner with leading drug development companies for companion diagnostic development.

Contact us

We have reached a crossroads in cancer treatment, where we can apply innovative tests on the patient’s blood and tumour tissue to select which patients need chemotherapy, what drugs will be most effective and what is a safe dose, reducing the risk of side effects. Our portfolio of biomarker tests allows us to make a step change in the treatment of early stage colorectal cancer, a disease affecting 1.2 million new patients every year, presenting a major global burden of morbidity and mortality.”

Prof. David Kerr CBE MD DSc FRCP (Glas, Lon, Edin) FRCGP FMedSci.

February 10, 2016

Job Opportunity: Project Manager Product Development

JOB DESCRIPTION PURPOSE: The role is based at Oxford Cancer Biomarkers (www.oxfordbio.com). Oxford Cancer Biomarkers translates ground-breaking scientific discovery into predictive biomarker diagnostic products that allow medicines to be personalised for the benefit of the cancer patient and is looking for a highly-motivated and results-oriented individual to join its team in the role of... more

January 18, 2016

Oxford Cancer Biomarkers announces Partnership with Room4

Oxford, UK, 18 January 2016 Oxford Cancer Biomarkers Ltd (OCB), the UK-based company developing tests that allow medicines to be personalised for the benefit of the cancer patient, has today announced a partnership with Room4 a UK based imaging company to deliver new tests for cancer prognosis. Room4 develops innovative high quality imaging software for pathology. OCB and Room4 have... more

December 14, 2015

Oxford Cancer Biomarkers announces new investment to commercialise its colorectal cancer diagnostic tests

Oxford, UK, 14 December 2015 Oxford Cancer Biomarkers Ltd (OCB), the UK-based company developing tests that allow medicines to be personalised for the benefit of the cancer patient, has today announced that it has secured new investment. Longwall Ventures co-invested with Esperante together with existing shareholders and a private investor. OCB has developed a suite of diagnostic tests for... more
doctor

Partnering with Pharmaceutical companies

We partner with leading pharmaceutical companies to develop cost effective companion biomarkers for pipeline drugs using our patented technology.

Learn more